Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eBATTLE Obesity
2023-506289-29-00Phase 4Authorised
- Sponsor
- Sykehuset i Vestfold
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Semaglutide arm with Placebo arm (2 arms). Primary endpoint: Percentage change in BMI. Planned start Feb 2025; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2023-506289-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506289-29-00.